RPM CD19-mbIL15-CAR-T cell therapy (Eden BioCell)

N/A

Report date: 2023/05/05 17:37:05

Base Information

Drug NameRPM CD19-mbIL15-CAR-T cell therapy (Eden BioCell)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19Gene transference
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEden BioCell Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEden BioCell Ltd
Active IndicationsN/A
Inactive IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[7] 

Other Information

ATC CodeN/A
Related LinksN/A